Cargando…

Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations

Adrenocorticotropic hormone (ACTH)-secreting pituitary tumors mainly express somatostatin receptor 5 (SSTR5) since SSTR2 is downregulated by the elevated levels of glucocorticoids that characterize patients with Cushing’s disease (CD). SSTR5 is the molecular target of pasireotide, the only approved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peverelli, Erika, Treppiedi, Donatella, Mantovani, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259348/ https://www.ncbi.nlm.nih.gov/pubmed/37435448 http://dx.doi.org/10.1530/EO-22-0042

Ejemplares similares

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019)

Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer
por: Treppiedi, Donatella, et al.
Publicado: (2022)

SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
por: Castellnou, Solène, et al.
Publicado: (2020)

Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas
por: Sbiera, Silviu, et al.
Publicado: (2016)

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant
por: Treppiedi, Donatella, et al.
Publicado: (2021)

OR23-04 SST5 Expression and USP8 Mutation in Functioning and Silent Corticotroph Pituitary Tumors
por: castellnou, Solene, et al.
Publicado: (2020)

Identification of a novel RASD1 somatic mutation in a USP8-mutated corticotroph adenoma
por: Uzilov, Andrew V., et al.
Publicado: (2017)

Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior
por: Mantovani, Giovanna, et al.
Publicado: (2019)

A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation
por: Mangili, Federica, et al.
Publicado: (2021)

High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma
por: Behling, Felix, et al.
Publicado: (2018)

Differential microRNA Expression in USP8-Mutated and Wild-Type Corticotroph Pituitary Tumors Reflect the Difference in Protein Ubiquitination Processes
por: Bujko, Mateusz, et al.
Publicado: (2021)

The Expression of Cell Cycle-Related Genes in USP8-Mutated Corticotroph Neuroendocrine Pituitary Tumors and Their Possible Role in Cell Cycle-Targeting Treatment
por: Mossakowska, Beata Joanna, et al.
Publicado: (2022)

SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors
por: Mangili, Federica, et al.
Publicado: (2020)

SAT-566 Cofilin Is a Mediator of RET-Promoted Medullary Thyroid Carcinoma Cell Migration, Invasion and Proliferation
por: Peverelli, Erika, et al.
Publicado: (2019)

SUN-213 The Role of Filamin A (FLNA) in the Regulation of Insulin-Like Growth Factor System in Adrenocortical Carcinomas
por: Peverelli, Erika, et al.
Publicado: (2020)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation
por: Treppiedi, Donatella, et al.
Publicado: (2022)

TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
por: Treppiedi, Donatella, et al.
Publicado: (2022)

PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022)

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023)

Response to Letter to the Editor from Lasolle and Raverot: “USP8 and TP53 Drivers Are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors”
por: Uzilov, Andrew V, et al.
Publicado: (2021)

Aggressive corticotroph tumors and carcinomas
por: Lasolle, Hélène, et al.
Publicado: (2022)

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations
por: Casar-Borota, Olivera, et al.
Publicado: (2020)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

Refractory corticotroph adenomas
por: Sumal, Amit K. S., et al.
Publicado: (2023)

USP8 mutation in Cushing's disease
por: Huang, Chuanxin, et al.
Publicado: (2015)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Glucocorticoid Receptors Are Making a Comeback in Corticotroph Tumorigenesis
por: Theodoropoulou, Marily
Publicado: (2021)

The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas
por: Regazzo, Daniela, et al.
Publicado: (2022)

Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4
por: Börzsei, Rita, et al.
Publicado: (2022)

Nuclear Receptors as Regulators of Pituitary Corticotroph Pro-Opiomelanocortin Transcription
por: Zhang, Dongyun, et al.
Publicado: (2020)

TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome
por: Perez-Rivas, Luis Gustavo, et al.
Publicado: (2022)

Recent Understanding and Future Directions of Recurrent Corticotroph Tumors
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2021)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
por: Wang, Ling, et al.
Publicado: (2013)

Pituitary Cachexia Treated with Corticotrophic Hormone
por: Hemphill, R. E.
Publicado: (1946)

A Case of Silent Corticotroph Adenoma
por: Ibekwe, Usonwanne U, et al.
Publicado: (2021)

Sex differences in pituitary corticotroph excitability
por: Duncan, Peter J., et al.
Publicado: (2023)

The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing’s disease and silent corticotroph tumors
por: Kober, Paulina, et al.
Publicado: (2023)

Recurrent gain-of-function USP8 mutations in Cushing's disease
por: Ma, Zeng-Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a7or2l7m2q1epqiqefltemuqod